Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-24 02:34 | 2025-06-20 | THAR | Canton Strategic Holdings, Inc. | Parikh Sanam | Director | BUY | $1.45 | 1,000 | $1,450 | 1,770 |
| 2025-06-24 02:31 | 2025-06-20 | THAR | Canton Strategic Holdings, Inc. | Appajosyula Sireesh | Director, Officer | BUY | $1.48 | 61,496 | $90,971 | 64,868 |
| 2025-06-24 04:29 | 2025-06-20 | THAR | Canton Strategic Holdings, Inc. | Gravitas Capital LP | Director, Officer, 10% owner | BUY | $1.48 | 337,838 | $500,000 | 732,424 |
| 2025-06-23 16:09 | 2025-06-18 | IMRX | Immuneering Corp | Feinberg Peter | Director | BUY | $2.53 | 25,000 | $63,188 | 136,766 |
| 2025-06-23 23:35 | 2025-06-23 | MBRX | Moleculin Biotech, Inc. | KLEMP WALTER V | Director, Officer | BUY | $0.37 | 675,675 | $250,000 | 743,607 |
| 2025-06-24 03:05 | 2025-06-20 | ORIC | Oric Pharmaceuticals, Inc. | You Angie | Director | BUY | $9.39 | 28,000 | $262,898 | 28,000 |
| 2025-06-23 18:35 | 2025-06-18 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% owner | SELL | $11.46 | 1,142,273 | $13,084,851 | 37,284,108 |
| 2025-06-24 02:42 | 2025-06-20 | AXSM | Axsome Therapeutics, Inc. | Murdock Hunter R. | Officer | OPT+S | $101.42 | 13,514 | $1,370,647 | 0 |
| 2025-06-23 23:10 | 2025-06-20 | ZLAB | Zai Lab Ltd | Lis William | Director | SELL | $35.67 | 13,814 | $492,745 | 35,106 |
| 2025-06-23 23:35 | 2025-06-23 | MBRX | Moleculin Biotech, Inc. | Foster Jonathan P. | Officer | BUY | $0.37 | 270,270 | $100,000 | 287,587 |
| 2025-06-23 20:50 | 2025-06-20 | RARE | Ultragenyx Pharmaceutical Inc. | Sanders Corazon (Corsee) D. | Director | SELL | $37.39 | 2,405 | $89,923 | 15,344 |
| 2025-06-23 16:38 | 2025-06-13 | RZLT | Rezolute, Inc. | Kim Young-Jin | Director | BUY | $3.25 | 1,230,769 | $3,999,999 | 8,423,386 |
| 2025-06-23 16:12 | 2025-06-13 | RZLT | Rezolute, Inc. | KREHER NERISSA | Director | BUY | $3.25 | 3,076 | $9,997 | 37,576 |
| 2025-06-23 21:39 | 2025-06-20 | SVRA | Savara Inc | Hawkins Richard J | Director | BUY | $2.04 | 48,225 | $98,572 | 115,466 |
| 2025-06-24 02:44 | 2025-06-18 | AIMD | Ainos Inc. | TSAI CHUN-JUNG | Director | SELL | $0.53 | 25,903 | $13,625 | 1,401,997 |
| 2025-06-20 16:35 | 2025-06-18 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | Director, Officer | BUY | $2.30 | 2,178 | $4,999 | 1,138,437 |
| 2025-06-20 16:35 | 2025-06-18 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | Director, Officer | BUY | $2.28 | 2,225 | $5,071 | 288,059 |
| 2025-06-21 03:58 | 2025-06-20 | CNTA | Centessa Pharmaceuticals plc | SAHA SAURABH | Director, Officer | OPT+S | $12.63 | 55,000 | $694,826 | 221,017 |
| 2025-06-20 16:50 | 2025-06-17 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $8.06 | 33,442 | $269,532 | 2,976,203 |
| 2025-06-20 16:09 | 2025-06-18 | IMRX | Immuneering Corp | Zeskind Benjamin J. | Director, Officer, 10% owner | BUY | $2.39 | 21,000 | $50,144 | 2,302,852 |
| 2025-06-20 23:32 | 2025-06-18 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $13.37 | 10,139 | $135,574 | 109,414 |
| 2025-06-20 23:20 | 2025-06-20 | CLYM | Climb Bio, Inc. | Pimblett Emily | Officer | OPT+S | $1.24 | 1,242 | $1,540 | 18,888 |
| 2025-06-21 04:09 | 2025-06-18 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | SELL | $54.84 | 6,620 | $363,041 | 549,867 |
| 2025-06-21 04:08 | 2025-06-20 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | Officer | SELL | $54.59 | 875 | $47,766 | 31,698 |
| 2025-06-21 04:07 | 2025-06-18 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | SELL | $54.84 | 1,129 | $61,914 | 166,234 |
| 2025-06-21 04:07 | 2025-06-18 | AKRO | Akero Therapeutics, Inc. | White William Richard | Officer | SELL | $54.84 | 1,634 | $89,609 | 57,521 |
| 2025-06-21 04:07 | 2025-06-18 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | SELL | $54.84 | 1,633 | $89,554 | 90,598 |
| 2025-06-21 04:06 | 2025-06-18 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | SELL | $54.84 | 1,453 | $79,683 | 196,594 |
| 2025-06-20 16:22 | 2025-06-16 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | OPT+S | $54.23 | 10,000 | $542,306 | 92,231 |
| 2025-06-20 16:22 | 2025-06-16 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | Officer | OPT+S | $54.14 | 2,000 | $108,272 | 32,573 |
| 2025-06-21 01:38 | 2025-06-18 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Officer | OPT+S | $16.00 | 15,000 | $240,000 | 7,696 |
| 2025-06-21 04:08 | 2025-06-18 | AKRO | Akero Therapeutics, Inc. | Gangloff Scott A. | Officer | SELL | $54.84 | 848 | $46,504 | 23,452 |
| 2025-06-21 02:43 | 2025-06-16 | QURE | uniQure N.V. | Potts Jeannette | Officer | SELL | $15.14 | 4,670 | $70,704 | 115,073 |
| 2025-06-20 23:05 | 2025-06-17 | AKTX | Akari Therapeutics Plc ADR | Gaslightwala Abizer | Director, Officer | BUY | $1.20 | 15,000 | $18,000 | 261,428 |
| 2025-06-20 18:22 | 2025-06-16 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $5.65 | 335 | $1,893 | 461,647 |
| 2025-06-20 18:21 | 2025-06-16 | VSTM | Verastem, Inc. | Stuglik Brian M | Director | SELL | $5.65 | 594 | $3,356 | 102,326 |
| 2025-06-20 18:22 | 2025-06-16 | VSTM | Verastem, Inc. | Gagnon Robert E. | Director | SELL | $5.65 | 284 | $1,605 | 42,242 |
| 2025-06-20 23:08 | 2025-06-18 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Director, Officer | SELL | $1.79 | 1,790 | $3,204 | 320,069 |
| 2025-06-21 00:42 | 2025-06-17 | TYRA | Tyra Biosciences, Inc. | KAPLAN GILLA | Director | SELL | $9.78 | 9,578 | $93,700 | 28,231 |
| 2025-06-20 23:06 | 2025-06-18 | ANAB | AnaptysBio Inc. | RENTON HOLLINGS | Director | SELL | $23.97 | 3,015 | $72,270 | 4,965 |
| 2025-06-20 23:07 | 2025-06-18 | ANAB | AnaptysBio Inc. | FENTON DENNIS M | Director | SELL | $23.97 | 3,015 | $72,270 | 4,965 |
| 2025-06-21 03:15 | 2025-06-17 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer | OPT+S | $6.74 | 339,720 | $2,289,781 | 912,419 |
| 2025-06-18 23:15 | 2025-06-16 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $11.00 | 8,500 | $93,522 | 443,642 |
| 2025-06-19 00:12 | 2025-06-16 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | Officer | OPT+S | $10.43 | 15,829 | $165,096 | 0 |
| 2025-06-18 23:05 | 2025-06-16 | NUVB | Nuvation Bio Inc. | Sauvage Philippe | Officer | BUY | $1.81 | 7,300 | $13,215 | 9,902 |
| 2025-06-18 23:05 | 2025-06-16 | NUVB | Nuvation Bio Inc. | Sjogren Colleen | Officer | BUY | $1.81 | 50,000 | $90,350 | 81,000 |
| 2025-06-18 23:05 | 2025-06-18 | NUVB | Nuvation Bio Inc. | Markel Stacy | Officer | BUY | $1.71 | 10,000 | $17,100 | 29,591 |
| 2025-06-18 23:39 | 2025-06-16 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $28.28 | 17,300 | $489,244 | 61,563 |
| 2025-06-18 23:11 | 2025-06-16 | AMRX | Amneal Pharmaceuticals Inc. | Patel Gautam | Director | SELL | $8.02 | 94,906 | $761,146 | 1,609,144 |
| 2025-06-18 23:56 | 2025-06-16 | XLO | Xilio Therapeutics, Inc. | Russo Rene | Director, Officer | BUY | $0.68 | 36,289 | $24,680 | 281,172 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.